CANCER THERAPY

Combining checkpoint inhibition and targeted therapy in melanoma

Article metrics

The combination of BRAF and MEK inhibition and anti-PD-1 is tolerable and has promising efficacy, which warrants further investigation into its use as melanoma therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Combined checkpoint inhibition and targeted therapy for melanoma.

References

  1. 1.

    Long, G. V. et al. J. Clin. Oncol. 36, 667–673 (2018).

  2. 2.

    Larkin, J. et al. N. Engl. J. Med. 371, 1867–1876 (2014).

  3. 3.

    Long, G. V. et al. Am. J. Clin. Oncol. 36, 9503–9503 (2018).

  4. 4.

    Hodi, F. S. et al. Lancet Oncol. 19, 1480–1492 (2018).

  5. 5.

    Ribas, A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0476-5 (2019).

  6. 6.

    Sullivan, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0474-7 (2019).

  7. 7.

    Ascierto, P. A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0448-9 (2019).

  8. 8.

    Robert, L., Ribas, A. & Hu-Lieskovan, S. Semin. Immunol. 28, 73–80 (2016).

  9. 9.

    Wilmott, J. S. et al. Clin. Cancer Res. 18, 1386–1394 (2012).

  10. 10.

    Frederick, D. T. et al. Clin. Cancer Res. 19, 1225–1231 (2013).

  11. 11.

    Hu-Lieskovan, S. et al. Sci. Transl. Med. 7, 279ra241 (2015).

  12. 12.

    Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. N. Engl. J. Med. 368, 1365–1366 (2013).

  13. 13.

    Minor, D. R., Puzanov, I., Callahan, M. K., Hug, B. A. & Hoos, A. Pigment Cell Melanoma Res. 28, 611–612 (2015).

  14. 14.

    Deken, M. A. et al. OncoImmunology 5, e1238557 (2016).

  15. 15.

    Rozeman, E. A. et al. Ann. Oncol. 29, mdy424-056 (2018).

Download references

Author information

Correspondence to Christian U. Blank.

Ethics declarations

Competing interests

E.A.R. received travel support from MSD and NanoString. C.U.B. reports personal fees as a consultant advisor for Bristol-Myers Squibb, Merck Sharpe Dohme, Roche, Novartis, Lilly, Pfizer, GlaxoSmithKline, GenMab and Pierre Fabre and has received research grants from Bristol-Myers Squibb, Novartis, and NanoString, all paid to the institution (Netherlands Cancer Institute).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark